외상성 뇌손상 역학 분석 및 예측(2026년)

The Global Traumatic Brain Injury prevelance is set to reach 50.52 million patients in 2035, growing at a CAGR of 2.2% from 41.37 million patients in 2026.

Traumatic brain injury is one of the leading causes of death and long-term disability worldwide, affecting individuals across all age groups. The condition ranges from mild concussion to severe brain trauma and is associated with significant neurological, cognitive, behavioral, and physical impairment. Although advances in trauma care have improved survival rates, the long-term disease burden continues to increase because more patients survive with chronic neurological disability.

Market Drivers

Rising Incidence of Traumatic Brain Injury

• Road traffic collisions, falls, workplace injuries, sports participation, and violence remain the leading contributors to traumatic brain injury globally. Population growth and aging continue to increase the absolute number of TBI cases despite improvements in injury prevention.

Improvements in Diagnosis

• Greater availability of CT imaging, MRI, blood biomarkers, standardized neurological assessment, and trauma registries has improved identification of traumatic brain injury across healthcare systems. Earlier diagnosis is strengthening epidemiological surveillance and patient management.

Growing Awareness

• Increasing public awareness of concussion, sports-related brain injury, and long-term neurological consequences has encouraged earlier medical evaluation and improved disease reporting. Educational initiatives have also strengthened physician recognition of mild traumatic brain injury.

Expansion of Epidemiological Research

• Large-scale population studies, electronic health records, national trauma databases, and Global Burden of Disease (GBD) research continue improving understanding of disease distribution, risk factors, and long-term outcomes across different populations.

Market Restraints

Underreporting of Mild TBI

• Many patients with mild traumatic brain injury do not seek medical attention, leading to underestimation of the true disease burden in epidemiological studies.

Regional Differences in Data Quality

• Variation in trauma registries, healthcare access, reporting standards, and diagnostic capabilities creates inconsistencies in epidemiological estimates across countries.

Limited Long-Term Follow-Up

• Long-term neurological, cognitive, and psychiatric consequences are not consistently captured in routine healthcare databases, limiting comprehensive disease burden assessment.

Epidemiology Insights

• The global traumatic brain injury epidemiology landscape can be segmented by injury severity, cause of injury, age group, gender, disease burden, and geography.
• By injury severity, the epidemiology includes mild, moderate, and severe traumatic brain injury. Mild traumatic brain injury accounts for the majority of diagnosed cases, while moderate and severe injuries contribute disproportionately to mortality, disability, and healthcare expenditure.
• By cause of injury, cases arise from road traffic accidents, falls, sports injuries, occupational accidents, interpersonal violence, military trauma, and other external injuries. Falls represent the leading cause globally, particularly among older adults, while road traffic accidents remain a major contributor among younger populations.
• By age group, the disease burden includes pediatric patients, adolescents, adults, and elderly populations. Children and young adults experience higher rates of sports and road injury-related TBI, while falls account for the majority of cases among elderly individuals. Older adults also experience poorer long-term outcomes because of age-related comorbidities.
• By gender, epidemiological studies consistently report higher incidence among males because of greater exposure to occupational hazards, contact sports, military activities, and road traffic injuries. However, the burden among females continues to increase owing to aging populations and fall-related injuries.

Epidemiological Trends

• The traumatic brain injury epidemiology landscape continues to evolve.

Key trends include:

• Increasing absolute number of TBI cases worldwide.
• Declining age-standardized incidence rates in several regions.
• Rising burden associated with population aging.
• Improved identification of mild traumatic brain injury.
• Greater use of trauma registries and electronic health records.
• Expansion of biomarker-based diagnosis.
• Increasing focus on long-term neurological outcomes.

Regional Insights

• North America remains one of the leading regions for traumatic brain injury surveillance because of advanced trauma systems, comprehensive injury registries, widespread neuroimaging availability, and strong epidemiological research infrastructure.
• Europe continues to maintain extensive epidemiological monitoring through national trauma databases, collaborative neurological research, and standardized injury reporting systems. Some regions report among the highest prevalence of long-term disability related to TBI.
• Asia-Pacific is expected to experience substantial growth in the reported disease burden owing to rapid urbanization, increasing motor vehicle use, expanding healthcare infrastructure, and improved diagnosis across developing healthcare systems.
• Latin America and the Middle East & Africa continue strengthening trauma surveillance systems, although disease burden remains underestimated because of limited reporting infrastructure and unequal healthcare access.

Disease Burden Landscape

• The epidemiological burden of traumatic brain injury extends beyond acute mortality to include persistent neurological disability, cognitive impairment, psychiatric disorders, reduced quality of life, and long-term rehabilitation needs. Increasing use of national registries, longitudinal cohort studies, and population health databases is improving understanding of disease progression and healthcare utilization, supporting future clinical research and healthcare planning.

Future Outlook

• The future of traumatic brain injury epidemiology will be shaped by continued improvements in trauma surveillance, digital health technologies, artificial intelligence-assisted diagnostics, biomarker research, and standardized reporting methodologies. Earlier diagnosis, enhanced data collection, and improved global collaboration are expected to strengthen epidemiological evidence while supporting development of targeted prevention strategies and innovative therapies.

Conclusion

• The Global Traumatic Brain Injury Epidemiology Analysis demonstrates that traumatic brain injury remains a major global public health challenge with substantial clinical, social, and economic consequences. Although advances in trauma care have improved survival, the growing number of individuals living with long-term neurological disability continues to increase the global disease burden. Continued investment in epidemiological research, prevention initiatives, standardized surveillance, and improved diagnostic capabilities will remain essential for reducing the future impact of traumatic brain injury.

Key Benefits of this Report

• Comprehensive assessment of the global traumatic brain injury epidemiological landscape.
• Detailed analysis of incidence, prevalence, disease burden, mortality, and demographic trends.
• Evaluation of risk factors, injury patterns, and regional epidemiological differences.
• Insights supporting clinical research, healthcare planning, and prevention strategies.
• Valuable resource for pharmaceutical companies, biotechnology firms, healthcare providers, researchers, policymakers, and investors.

What Businesses Use Our Reports For

• Epidemiological forecasting, patient population assessment, clinical trial planning, healthcare resource allocation, commercial opportunity evaluation, public health planning, investment analysis, market strategy development, and long-term decision-making.

Report Coverage

• Historical data from 2021 to 2024, Base Year 2025, and Forecast Period 2026 to 2035
• Comprehensive analysis of global traumatic brain injury epidemiology by injury severity, cause of injury, age group, gender, disease burden, and geography
• Evaluation of incidence, prevalence, mortality, disability burden, demographic distribution, injury mechanisms, and epidemiological trends
• Assessment of trauma registries, diagnostic practices, healthcare utilization, long-term outcomes, and regional disease burden
• Analysis of mild, moderate, and severe traumatic brain injury, road traffic injuries, falls, sports-related injuries, occupational trauma, military injuries, and future epidemiological trends through 2035.

TABLE OF CONTENTS

1. Executive Summary

• 1.1 Report Scope and Objectives
• 1.2 Key Findings
• 1.3 Epidemiology Highlights
• 1.4 Global Disease Burden Overview
• 1.5 Key Epidemiological Trends
• 1.6 Diagnosed Population Overview
• 1.7 Forecast Highlights (2026-2035)
• 1.8 Future Outlook

2. Disease Overview

• 2.1 Introduction to Traumatic Brain Injury (TBI)
• 2.2 Disease Definition and Classification
• 2.3 Pathophysiology
• 2.4 Causes and Risk Factors
  • 2.4.1 Falls
  • 2.4.2 Road Traffic Accidents
  • 2.4.3 Sports-Related Injuries
  • 2.4.4 Occupational Injuries
  • 2.4.5 Violence and Assaults
  • 2.4.6 Military and Blast Injuries
• 2.5 Clinical Manifestations
• 2.6 Disease Severity Classification
  • 2.6.1 Mild TBI
  • 2.6.2 Moderate TBI
  • 2.6.3 Severe TBI
• 2.7 Disease Burden and Disability Impact
• 2.8 Mortality and Long-Term Outcomes

3. Epidemiology Methodology

• 3.1 Research Methodology
• 3.2 Epidemiology Modeling Framework
• 3.3 Data Collection and Validation
• 3.4 Historical Data Analysis (2021-2025)
• 3.5 Forecasting Methodology (2026-2035)
• 3.6 Key Assumptions
• 3.7 Data Sources and References

4. Global Epidemiology Analysis

• 4.1 Total Prevalence
• 4.2 Total Incidence
• 4.3 Diagnosed Cases
• 4.4 Undiagnosed Cases
• 4.5 Hospitalized Cases
• 4.6 Emergency Department Cases
• 4.7 Treated Cases
• 4.8 Disability-Associated Cases
• 4.9 Mortality Analysis
• 4.10 Forecast Analysis (2026-2035)

5. Epidemiology Analysis by Disease Severity

• 5.1 Mild Traumatic Brain Injury
  • 5.1.1 Total Prevalence
  • 5.1.2 Total Incidence
  • 5.1.3 Diagnosed Cases
  • 5.1.4 Hospitalized Cases
  • 5.1.5 Forecast Analysis
• 5.2 Moderate Traumatic Brain Injury
  • 5.2.1 Total Prevalence
  • 5.2.2 Total Incidence
  • 5.2.3 Diagnosed Cases
  • 5.2.4 Hospitalized Cases
  • 5.2.5 Forecast Analysis
• 5.3 Severe Traumatic Brain Injury
  • 5.3.1 Total Prevalence
  • 5.3.2 Total Incidence
  • 5.3.3 Diagnosed Cases
  • 5.3.4 Hospitalized Cases
  • 5.3.5 Forecast Analysis

6. Epidemiology Analysis by Cause of Injury

• 6.1 Falls
  • 6.1.1 Total Cases
  • 6.1.2 Diagnosed Cases
  • 6.1.3 Age Distribution
  • 6.1.4 Gender Distribution
  • 6.1.5 Forecast Analysis
• 6.2 Road Traffic Accidents
  • 6.2.1 Total Cases
  • 6.2.2 Diagnosed Cases
  • 6.2.3 Age Distribution
  • 6.2.4 Gender Distribution
  • 6.2.5 Forecast Analysis
• 6.3 Sports and Recreational Injuries
  • 6.3.1 Total Cases
  • 6.3.2 Diagnosed Cases
  • 6.3.3 Age Distribution
  • 6.3.4 Gender Distribution
  • 6.3.5 Forecast Analysis
• 6.4 Occupational Injuries
  • 6.4.1 Total Cases
  • 6.4.2 Diagnosed Cases
  • 6.4.3 Age Distribution
  • 6.4.4 Gender Distribution
  • 6.4.5 Forecast Analysis
• 6.5 Violence and Assaults
  • 6.5.1 Total Cases
  • 6.5.2 Diagnosed Cases
  • 6.5.3 Age Distribution
  • 6.5.4 Gender Distribution
  • 6.5.5 Forecast Analysis
• 6.6 Military and Blast Injuries
  • 6.6.1 Total Cases
  • 6.6.2 Diagnosed Cases
  • 6.6.3 Age Distribution
  • 6.6.4 Gender Distribution
  • 6.6.5 Forecast Analysis

7. Epidemiology Analysis by Age Group

• 7.1 Pediatric Population (0-17 Years)
  • 7.1.1 Total Prevalence
  • 7.1.2 Total Incidence
  • 7.1.3 Diagnosed Cases
  • 7.1.4 Forecast Analysis
• 7.2 Young Adult Population (18-34 Years)
  • 7.2.1 Total Prevalence
  • 7.2.2 Total Incidence
  • 7.2.3 Diagnosed Cases
  • 7.2.4 Forecast Analysis
• 7.3 Adult Population (35-64 Years)
  • 7.3.1 Total Prevalence
  • 7.3.2 Total Incidence
  • 7.3.3 Diagnosed Cases
  • 7.3.4 Forecast Analysis
• 7.4 Elderly Population (65 Years and Above)
  • 7.4.1 Total Prevalence
  • 7.4.2 Total Incidence
  • 7.4.3 Diagnosed Cases
  • 7.4.4 Forecast Analysis

8. Epidemiology Analysis by Gender

• 8.1 Male Population
  • 8.1.1 Total Prevalence
  • 8.1.2 Total Incidence
  • 8.1.3 Diagnosed Cases
  • 8.1.4 Hospitalized Cases
  • 8.1.5 Forecast Analysis
• 8.2 Female Population
  • 8.2.1 Total Prevalence
  • 8.2.2 Total Incidence
  • 8.2.3 Diagnosed Cases
  • 8.2.4 Hospitalized Cases
  • 8.2.5 Forecast Analysis

9. Diagnosed and Treated Population Analysis

• 9.1 Diagnosis Rate Assessment
• 9.2 Underdiagnosis Analysis
• 9.3 Hospitalization Trends
• 9.4 Emergency Care Utilization Trends
• 9.5 Rehabilitation-Eligible Population
• 9.6 Long-Term Care Population
• 9.7 Treated Population Forecast
• 9.8 Future Diagnostic Trends

10. Geographical Analysis

• 10.1 North America
  • 10.1.1 Total Prevalence
  • 10.1.2 Total Incidence
  • 10.1.3 Diagnosed Cases
  • 10.1.4 Disease Severity Distribution
  • 10.1.5 Age-Specific Epidemiology
  • 10.1.6 Gender-Specific Epidemiology
  • 10.1.7 Forecast Analysis
• 10.2 Europe
  • 10.2.1 Total Prevalence
  • 10.2.2 Total Incidence
  • 10.2.3 Diagnosed Cases
  • 10.2.4 Disease Severity Distribution
  • 10.2.5 Age-Specific Epidemiology
  • 10.2.6 Gender-Specific Epidemiology
  • 10.2.7 Forecast Analysis
• 10.3 Asia-Pacific
  • 10.3.1 Total Prevalence
  • 10.3.2 Total Incidence
  • 10.3.3 Diagnosed Cases
  • 10.3.4 Disease Severity Distribution
  • 10.3.5 Age-Specific Epidemiology
  • 10.3.6 Gender-Specific Epidemiology
  • 10.3.7 Forecast Analysis
• 10.4 Latin America
  • 10.4.1 Total Prevalence
  • 10.4.2 Total Incidence
  • 10.4.3 Diagnosed Cases
  • 10.4.4 Disease Severity Distribution
  • 10.4.5 Age-Specific Epidemiology
  • 10.4.6 Gender-Specific Epidemiology
  • 10.4.7 Forecast Analysis
• 10.5 Middle East & Africa
  • 10.5.1 Total Prevalence
  • 10.5.2 Total Incidence
  • 10.5.3 Diagnosed Cases
  • 10.5.4 Disease Severity Distribution
  • 10.5.5 Age-Specific Epidemiology
  • 10.5.6 Gender-Specific Epidemiology
  • 10.5.7 Forecast Analysis

11. Key Countries Analysis

• 11.1 United States
  • 11.1.1 Total Prevalence
  • 11.1.2 Total Incidence
  • 11.1.3 Diagnosed Cases
  • 11.1.4 Disease Severity Distribution
  • 11.1.5 Age-Specific Epidemiology
  • 11.1.6 Gender-Specific Epidemiology
  • 11.1.7 Forecast Analysis (2026-2035)
• 11.2 Canada
  • 11.2.1 Total Prevalence
  • 11.2.2 Total Incidence
  • 11.2.3 Diagnosed Cases
  • 11.2.4 Disease Severity Distribution
  • 11.2.5 Age-Specific Epidemiology
  • 11.2.6 Gender-Specific Epidemiology
  • 11.2.7 Forecast Analysis (2026-2035)
• 11.3 Germany
  • 11.3.1 Total Prevalence
  • 11.3.2 Total Incidence
  • 11.3.3 Diagnosed Cases
  • 11.3.4 Disease Severity Distribution
  • 11.3.5 Age-Specific Epidemiology
  • 11.3.6 Gender-Specific Epidemiology
  • 11.3.7 Forecast Analysis (2026-2035)
• 11.4 United Kingdom
  • 11.4.1 Total Prevalence
  • 11.4.2 Total Incidence
  • 11.4.3 Diagnosed Cases
  • 11.4.4 Disease Severity Distribution
  • 11.4.5 Age-Specific Epidemiology
  • 11.4.6 Gender-Specific Epidemiology
  • 11.4.7 Forecast Analysis (2026-2035)
• 11.5 France
  • 11.5.1 Total Prevalence
  • 11.5.2 Total Incidence
  • 11.5.3 Diagnosed Cases
  • 11.5.4 Disease Severity Distribution
  • 11.5.5 Age-Specific Epidemiology
  • 11.5.6 Gender-Specific Epidemiology
  • 11.5.7 Forecast Analysis (2026-2035)
• 11.6 Italy
  • 11.6.1 Total Prevalence
  • 11.6.2 Total Incidence
  • 11.6.3 Diagnosed Cases
  • 11.6.4 Disease Severity Distribution
  • 11.6.5 Age-Specific Epidemiology
  • 11.6.6 Gender-Specific Epidemiology
  • 11.6.7 Forecast Analysis (2026-2035)
• 11.7 Spain
  • 11.7.1 Total Prevalence
  • 11.7.2 Total Incidence
  • 11.7.3 Diagnosed Cases
  • 11.7.4 Disease Severity Distribution
  • 11.7.5 Age-Specific Epidemiology
  • 11.7.6 Gender-Specific Epidemiology
  • 11.7.7 Forecast Analysis (2026-2035)
• 11.8 China
  • 11.8.1 Total Prevalence
  • 11.8.2 Total Incidence
  • 11.8.3 Diagnosed Cases
  • 11.8.4 Disease Severity Distribution
  • 11.8.5 Age-Specific Epidemiology
  • 11.8.6 Gender-Specific Epidemiology
  • 11.8.7 Forecast Analysis (2026-2035)
• 11.9 Japan
  • 11.9.1 Total Prevalence
  • 11.9.2 Total Incidence
  • 11.9.3 Diagnosed Cases
  • 11.9.4 Disease Severity Distribution
  • 11.9.5 Age-Specific Epidemiology
  • 11.9.6 Gender-Specific Epidemiology
  • 11.9.7 Forecast Analysis (2026-2035)
• 11.10 India
  • 11.10.1 Total Prevalence
  • 11.10.2 Total Incidence
  • 11.10.3 Diagnosed Cases
  • 11.10.4 Disease Severity Distribution
  • 11.10.5 Age-Specific Epidemiology
  • 11.10.6 Gender-Specific Epidemiology
  • 11.10.7 Forecast Analysis (2026-2035)
• 11.11 South Korea
  • 11.11.1 Total Prevalence
  • 11.11.2 Total Incidence
  • 11.11.3 Diagnosed Cases
  • 11.11.4 Disease Severity Distribution
  • 11.11.5 Age-Specific Epidemiology
  • 11.11.6 Gender-Specific Epidemiology
  • 11.11.7 Forecast Analysis (2026-2035)
• 11.12 Australia
  • 11.12.1 Total Prevalence
  • 11.12.2 Total Incidence
  • 11.12.3 Diagnosed Cases
  • 11.12.4 Disease Severity Distribution
  • 11.12.5 Age-Specific Epidemiology
  • 11.12.6 Gender-Specific Epidemiology
  • 11.12.7 Forecast Analysis (2026-2035)

12. Company Profiles

• 12.1 Abbott Laboratories
  • 12.1.1 Overview
  • 12.1.2 Financials
  • 12.1.3 TBI Diagnostics Portfolio
  • 12.1.4 Epidemiology and Research Initiatives
  • 12.1.5 Key Products and Technologies
  • 12.1.6 Recent Developments
• 12.2 Banyan Biomarkers, Inc.
  • 12.2.1 Overview
  • 12.2.2 Financials
  • 12.2.3 TBI Biomarker Portfolio
  • 12.2.4 Epidemiology and Research Initiatives
  • 12.2.5 Key Products and Technologies
  • 12.2.6 Recent Developments
• 12.3 BrainScope Company, Inc.
  • 12.3.1 Overview
  • 12.3.2 Financials
  • 12.3.3 TBI Assessment Portfolio
  • 12.3.4 Epidemiology and Research Initiatives
  • 12.3.5 Key Products and Technologies
  • 12.3.6 Recent Developments
• 12.4 Integra LifeSciences Holdings Corporation
  • 12.4.1 Overview
  • 12.4.2 Financials
  • 12.4.3 Neurocritical Care Portfolio
  • 12.4.4 Epidemiology and Research Initiatives
  • 12.4.5 Key Products and Technologies
  • 12.4.6 Recent Developments
• 12.5 Medtronic plc
  • 12.5.1 Overview
  • 12.5.2 Financials
  • 12.5.3 Neurotechnology Portfolio
  • 12.5.4 Epidemiology and Research Initiatives
  • 12.5.5 Key Products and Technologies
  • 12.5.6 Recent Developments
• 12.6 Nihon Kohden Corporation
  • 12.6.1 Overview
  • 12.6.2 Financials
  • 12.6.3 Neuromonitoring Portfolio
  • 12.6.4 Epidemiology and Research Initiatives
  • 12.6.5 Key Products and Technologies
  • 12.6.6 Recent Developments
• 12.7 Natus Medical Incorporated
  • 12.7.1 Overview
  • 12.7.2 Financials
  • 12.7.3 Neurodiagnostic Portfolio
  • 12.7.4 Epidemiology and Research Initiatives
  • 12.7.5 Key Products and Technologies
  • 12.7.6 Recent Developments
• 12.8 Koninklijke Philips N.V.
  • 12.8.1 Overview
  • 12.8.2 Financials
  • 12.8.3 Neuroimaging and Monitoring Portfolio
  • 12.8.4 Epidemiology and Research Initiatives
  • 12.8.5 Key Products and Technologies
  • 12.8.6 Recent Developments
• 12.9 GE HealthCare Technologies Inc.
  • 12.9.1 Overview
  • 12.9.2 Financials
  • 12.9.3 Neuroimaging Portfolio
  • 12.9.4 Epidemiology and Research Initiatives
  • 12.9.5 Key Products and Technologies
  • 12.9.6 Recent Developments
• 12.10 Siemens Healthineers AG
  • 12.10.1 Overview
  • 12.10.2 Financials
  • 12.10.3 Neuroimaging Portfolio
  • 12.10.4 Epidemiology and Research Initiatives
  • 12.10.5 Key Products and Technologies
  • 12.10.6 Recent Developments

13. Patient Journey Analysis

• 13.1 Injury Occurrence to Diagnosis Pathway
• 13.2 Emergency Care Pathway
• 13.3 Hospitalization Trends
• 13.4 Rehabilitation Referral Patterns
• 13.5 Long-Term Follow-Up Trends
• 13.6 Patient Retention and Monitoring Patterns

14. Disease Burden Assessment

• 14.1 Clinical Burden
• 14.2 Disability Burden
• 14.3 Economic Burden
• 14.4 Healthcare Resource Utilization
• 14.5 Productivity Loss Assessment
• 14.6 Caregiver Burden
• 14.7 Future Disease Burden Outlook

15. Future Epidemiology Outlook

• 15.1 Epidemiological Trends Through 2035
• 15.2 Aging Population Impact
• 15.3 Road Safety and Prevention Impact
• 15.4 Advances in Diagnosis and Reporting
• 15.5 Future Patient Population Outlook

16. Appendix

• 16.1 Abbreviations
• 16.2 References
• 16.3 Epidemiology Data Sources
• 16.4 Government and Public Health Sources
• 16.5 Scientific Literature Sources